ALNY Earnings Prediction
The chart below shows how ALNY performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ALNY sees a +3.32% change in stock price 10 days leading up to the earnings, and a -1.01% change 10 days following the report. On the earnings day itself, the stock moves by -0.10%. This data can give you a slight idea of what to expect for the next quarter's release.
ALNY Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
593.17M
34.90%
18.42%
Gross Margin
82.67%
2.73%
-0.22%
Operating Margin
-17.73%
-33.02%
15.50%
Net Margin
-14.12%
-54.96%
-36.60%
EPS
-0.65
-40.91%
-25.29%
No Data Available
ALNY Earnings Analysis
Alnylam Pharmaceuticals Inc Corporation (ALNY.O) Earnings Conference Call
Positive
Business Progress and Success: 2024 was a fantastic year for Alnylam with strong research, program development and commercial execution and significant progress across the business.
Record Revenue Achievement: Achieved combined net product revenues of over $1.6 billion at the upper end of revised guidance range, marking a 33% growth compared to 2023.
Non-GAAP Operating Income Milestone: Delivered $95 million in non-GAAP operating income for the full year, a significant milestone for the company.
TTR Franchise Revenue Surge: The TTR franchise achieved $343 million in global net product revenues during Q4, representing a 35% increase compared to Q4 2023.
Sales Growth Analysis: In the U.S., combined sales of ONPATTRO and AMVUTTRA increased by 10% compared to Q3 and finished the year with a robust 42% year-over-year increase.
AMVUTTRA Launch Preparation: The company is preparing for the potential launch of AMVUTTRA for ATTR cardiomyopathy, with a PDUFA date of March 23, 2025.
TTR Sales Projection Increase: For 2025, Alnylam projects TTR product sales of between $1.6 billion and $1.725 billion, representing a 36% increase compared to 2024 at the midpoint of guidance.
Orphan Drug Designation: The FDA granted Nucresiran orphan drug designation for ATTR Amyloidosis, supporting its potential as a best-in-class profile.
Global Revenue Growth 2024: Total global net product revenues for 2024 were $1.646 billion, representing 33% growth versus 2023, with both TTR and Rare franchises reporting strong growth of 34% and 29%, respectively.
Cash and Marketable Securities Growth: The company ended the year with cash, cash equivalents and marketable securities of $2.7 billion, an increase from $2.4 billion at the end of 2023.
Negative
Earnings Miss Reported: Alnylam Pharmaceuticals missed earnings expectations with a reported EPS of $-0.65, falling short of the expected $-0.62.
Collaboration Revenue Decline: Despite strong revenue growth, the company faced a decline in collaboration revenues by 7% compared to 2023, attributed to differences in revenue items between the two years.
Franchise Sales Decline: The Rare franchise saw a 3% decline in combined product sales in Q4 compared to the previous quarter, indicating potential challenges in maintaining momentum.
GIVLAARI Sales Decline: GIVLAARI product sales decreased by 9% compared to the third quarter of 2024, primarily due to the timing of large orders that did not recur in Q4.
Gross Margin Decrease Anticipated: The company anticipates a decrease in gross margin on product sales for 2025 due to an expected higher average royalty rate payable on AMVUTTRA as sales increase.
ALNY FAQs
How does ALNY typically perform around its earnings report dates?
Is Alnylam Pharmaceuticals Inc (ALNY) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ALNY Earning Call Sentiment
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2024 Earnings Call Transcript
ALNY.O
-1.3%Positive
The earnings call reveals strong financial performance with significant revenue growth and improved operating income. Despite some uncertainties in the Q&A regarding payer policies and pricing adjustments, the overall sentiment is positive due to optimistic guidance, a strong product pipeline, and significant cash reserves. The lack of a shareholder return plan slightly tempers the outlook, but the positive financial metrics and guidance suggest a likely stock price increase of 2% to 8% in the near term.
